Sustained delivery of a HIF-1 antagonist for ocular neovascularization

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 625-633

  Iwase, Takeshi ^a   Fu, Jie ^a,b   Yoshida, Tsunehiko ^a   Muramatsu, Daisuke ^a   Miki, Akiko ^a   Hashida, Noriyasu ^a   Lu, Lili ^a   Oveson, Brian ^a   Lima E Silva, Raquel ^a   Seidel, Christopher ^a   Yang, Ming ^c   Connelly, Sheila ^c   Shen, Jikui ^a   Han, Bing ^a,b   Wu, Mingsheng ^a,b   Semenza, Gregg L ^d   Hanes, Justin ^a,b,d   Campochiaro, Peter A ^a,b  

^a Department of Ophthalmology ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c GrayBug   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Angiogenesis; Diabetic retinopathy; Nanoparticles

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; ANGIOGENESIS; BRANCHED POLYETHYLENES; DIABETIC RETINOPATHY; HYPOXIA-INDUCIBLE FACTOR 1; NEW CHEMICAL ENTITIES; RETINAL NEOVASCULARIZATION; TRANSCRIPTIONAL ACTIVITY;

EYE PROTECTION; OPHTHALMOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TOXICITY;

NANOPARTICLES;

COPOLYMER; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1; NANOPARTICLE; PLATELET DERIVED GROWTH FACTOR BB; POLY[(SEBACIC ACID) CO (POLYETHYLENE GLYCOL) 3 ]; RHODOPSIN; SEBACIC ACID; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; BRUCH MEMBRANE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ELECTRORETINOGRAM; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; RABBIT; RETINA NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TRANSGENIC MOUSE; VITREOUS BODY;

AGE-RELATED MACULAR DEGENERATION; ANGIOGENESIS; DIABETIC RETINOPATHY; NANOPARTICLES;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NANOPARTICLES; POLYETHYLENE GLYCOLS; RABBITS; RETINA; RETINAL NEOVASCULARIZATION;

EID: 84887159636     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.10.008     Document Type: Article

References (48)

1. J.C. Yang A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 2003 427 434 (Pubitemid 36910021)
2. H. Hurwitz Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342 (Pubitemid 38702844)
3. P.J. Rosenfeld Ranibizumab for neovascular age-related macular degeneration N. Engl. J. Med. 355 2006 1419 1431 (Pubitemid 44511557)
4. A.H. Shih Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis Cancer Res. 64 2004 4783 4789 (Pubitemid 38924521)
5. M.-S. Seo Photoreceptor-specific expression of PDGF-B results in traction retinal detachment Am. J. Pathol. 157 2000 995 1005
6. I. Kryczek CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers Cancer Res. 65 2005 465 472
7. B. Guleng Blockade of the stomal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner Cancer Res. 65 2005 5864 5871 (Pubitemid 40911192)
8. R. Lima e Silva The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization FASEB J. 21 2007 3219 3230 (Pubitemid 47565540)
9. A. Stratmann, W. Risau, and K.H. Plate Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis Am. J. Pathol. 153 1998 1459 1466 (Pubitemid 28509902)
10. J. Holash Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998 (Pubitemid 29309448)
11. S.F. Hackett, S.J. Wiegand, G. Yancopoulos, and P. Campochiaro Angiopoietin-2 plays an important role in retinal angiogenesis J. Cell. Physiol. 192 2002 182 187 (Pubitemid 34747786)
12. Y. Oshima Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor J. Cell. Physiol. 199 2004 412 417 (Pubitemid 38580437)
13. G. Bergers, S. Song, N. Meyer-Morse, E. Bersland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Investig. 111 2003 1287 1295 (Pubitemid 36554699)
14. R. Erber Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J. 18 2004 338 340
15. N. Jo Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization Am. J. Pathol. 168 2006 2036 2053 (Pubitemid 43825322)
16. K. Takahashi The multi-targeted kinase inhibitor pazopanib causes suppression and regression of choroidal neovascularization Arch. Ophthalmol. 127 2009 494 499
17. J.A. Forsythe Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Mol. Cell. Biol. 16 1996 4604 4613 (Pubitemid 26272112)
18. B.D. Kelly Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1 Circ. Res. 93 2003 1074 1081 (Pubitemid 37485038)
19. H. Zhang Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth Proc. Natl. Acad. Sci. U. S. A. 105 2008 19579 19586
20. K. Lee Antracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor induced mobilization of circulating angiogenic cells Proc. Natl. Acad. Sci. U. S. A. 106 2009 2353 2358
21. D. Hanahan, G. Bergers, and E. Bergsland Less is more, regularly: metronomic dosing of cytoxic drugs can target tumor angiogenesis in mice J. Clin. Investig. 105 2000 1045 1047 (Pubitemid 30217688)
22. T. Yoshida Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization FASEB J. 24 2010 1759-1767.
23. T. Tobe Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model Am. J. Pathol. 153 1998 1641 1646 (Pubitemid 28509922)
24. Y. Saishin VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier J. Cell. Physiol. 195 2003 241 248 (Pubitemid 36384298)
25. J.S. Heier The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as needed after 12-week fixed dosing Ophthalmology 118 2011 1098 1106
26. J. Shen In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels Investig. Ophthalmol. Vis. Sci. 48 2007 4335 4341 (Pubitemid 351261067)
27. N. Okamoto Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization Am. J. Pathol. 151 1 1997 281 291
28. T. Tobe Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors Investig. Ophthalmol. Vis. Sci. 39 1 1998 180 188 (Pubitemid 28040477)
29. R. Klein, B.E. Klein, and K.L. Linton Prevalence of age-related maculopathy. The Beaver Dam Eye Study Ophthalmology 99 1992 933 943
30. R. Klein, B.E. Klein, S.E. Moss, M.D. Davis, and D.L. DeMets The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch. Ophthalmol. 102 1984 527 532 (Pubitemid 14127839)
31. N. Kwak, N. Okamoto, J.M. Wood, and P.A. Campochiaro VEGF is an important stimulator in a model of choroidal neovascularization Investig. Ophthalmol. Vis. Sci. 41 2000 3158 3164
32. L.P. Aiello Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc. Natl. Acad. Sci. U. S. A. 92 1995 10457 10461
33. H. Ozaki Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates Exp. Eye Res. 64 4 1997 505 517 (Pubitemid 27321334)
34. H. Ozaki Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization Am. J. Pathol. 156 2000 679 707
35. D.M. Brown Ranibizumab versus verteporfin for neovascular age-related macular degeneration N. Engl. J. Med. 355 2006 1432 1444 (Pubitemid 44511558)
36. Group CR Ranibizumab and bevacizumab for neovascular age-related macular degeneration N. Engl. J. Med. 364 2011 1897 1908
37. J.F. Arevalo Intravitreal bevacizumab for proliferative diabetic retinopathy: 6 months follow-up Eye 23 2009 117 123
38. M.E. Iliev, D. Doming, U. Wolf-Schnurrbursch, S. Wolf, and G.M. Sarra Intravitreal bevacizumab in the treatment of neovascular glaucoma Am J. Ophthalmol. 142 2006 1054 1056 (Pubitemid 44853889)
39. D.S. Boyer, and Ophthotech Anti-PDGF in AMD Study Group Combined Inhibition of Platelet-Derived (PDGF) and Vascular Endothelial (VEGF) Growth Factors for the Treatment of Neovascular Age-Related Macular Degeneration (NV-AMD) Results of a phase 1 study Invest. Ophthalmol. Vis. Sci. Online ARVO abstract 1260 2009
40. K. Miki Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor Ophthalmology 116 2009 1748 1754
41. S. Ben-Shabat, N. Kumar, and A.J. Domb PEG-PLA block copolymer as potential drug carrier: preparation and characterization Macromol. Biosci. 6 2006 1019 1025 (Pubitemid 46032938)
42. K. Mori Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization J. Cell. Physiol. 188 2001 253 263 (Pubitemid 32622916)
43. G. Okoye Increased expression of BDNF preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage J. Neurosci. 23 2003 4164 4172 (Pubitemid 36958436)
44. K. Komeima, B.S. Rogers, L. Lu, and P.A. Campochiaro Antioxidants reduce cone cell death in a model of retinitis pigmentosa Proc. Natl. Acad. Sci. U. S. A. 103 2006 11300 11305 (Pubitemid 44159928)
45. K. Komeima, B.S. Rogers, and P.A. Campochiaro Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa J. Cell. Physiol. 213 2007 809 815 (Pubitemid 350058275)
46. K.I. Hartmann, A. Nieto, E.C. Wu, W.R. Freeman, J.S. Kim, J. Chhablani, M.J. Sailor, and L. Cheng Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for danorubicin J. Ocul. Pharmacol. Ther. 29 2013 493 500
47. E.C. Wu, J.S. Andrew, L. Cheng, W.R. Freeman, L. Pearson, and M.J. Sailor Real time monitoring of sustained drug release using optical properties of porous silicon photonic crystal particles Biomaterials 32 2011 1957 1966
48. J. Chhablain, A. Nieto, H. Hou, E.C. Wu, W.R. Freeman, M.J. Sailor, and L. Cheng Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system IOVS 54 2013 1268 1279